There has been an increased interest in pharmacokinetics and pharmacodynamics (PKPD)
of anti-tuberculosis drugs. A better understanding of the relationship between drug …

For rapid anti-tuberculosis (TB) drug development in vitro pharmacokinetic/
pharmacodynamic (PK/PD) models are useful in evaluating the direct interaction between …

Background Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science is vital to
early antibiotic drug development to enable more efficient dose-effect study designs …

Optimization of dosing strategies and companion drugs prior to Phase III trials is currently a
critical obstacle in the development of new anti-tuberculosis drugs. Pharmacokinetic …

Robust and physiologically relevant infection models are required to investigate
pharmacokinetic–pharmacodynamic (PK/PD) correlations for anti-tuberculosis agents at …

Robert Koch discovered Mycobacterium tuberculosis (Mtb), the causative agent of
tuberculosis (TB), in 1882 (Koch, 1882). Significant progress has been made since then to …

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …

Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent. The
currently used combination drug regimens produce cure rates that exceed 95%, given good …

Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial
simulations have not been adequately applied to the design of doses and dose schedules of …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …